AMRX
Price
$10.39
Change
-$0.01 (-0.10%)
Updated
Oct 3 closing price
Capitalization
3.26B
25 days until earnings call
VTRS
Price
$10.19
Change
+$0.08 (+0.79%)
Updated
Oct 3 closing price
Capitalization
11.88B
31 days until earnings call
Interact to see
Advertisement

AMRX vs VTRS

Header iconAMRX vs VTRS Comparison
Open Charts AMRX vs VTRSBanner chart's image
Amneal Pharmaceuticals
Price$10.39
Change-$0.01 (-0.10%)
Volume$1.84M
Capitalization3.26B
Viatris
Price$10.19
Change+$0.08 (+0.79%)
Volume$7.01M
Capitalization11.88B
AMRX vs VTRS Comparison Chart in %
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. VTRS commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and VTRS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (AMRX: $10.39 vs. VTRS: $10.19)
Brand notoriety: AMRX and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 108% vs. VTRS: 69%
Market capitalization -- AMRX: $3.26B vs. VTRS: $11.88B
AMRX [@Pharmaceuticals: Generic] is valued at $3.26B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $11.88B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.89B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, AMRX is a better buy in the long-term than VTRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 6 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 4 bearish.
  • VTRS’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, VTRS is a better buy in the short-term than AMRX.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +6.56% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +7.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.81%. For the same industry, the average monthly price growth was +6.75%, and the average quarterly price growth was +54.33%.

Reported Earning Dates

AMRX is expected to report earnings on Oct 30, 2025.

VTRS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.81% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($11.9B) has a higher market cap than AMRX($3.26B). AMRX has higher P/E ratio than VTRS: AMRX (1040.00) vs VTRS (236.20). AMRX YTD gains are higher at: 31.187 vs. VTRS (-14.981). AMRX has higher annual earnings (EBITDA): 584M vs. VTRS (-493.3M). VTRS has more cash in the bank: 809M vs. AMRX (71.5M). AMRX has less debt than VTRS: AMRX (2.58B) vs VTRS (14.8B). VTRS has higher revenues than AMRX: VTRS (14.1B) vs AMRX (2.85B).
AMRXVTRSAMRX / VTRS
Capitalization3.26B11.9B27%
EBITDA584M-493.3M-118%
Gain YTD31.187-14.981-208%
P/E Ratio1040.00236.20440%
Revenue2.85B14.1B20%
Total Cash71.5M809M9%
Total Debt2.58B14.8B17%
FUNDAMENTALS RATINGS
AMRX vs VTRS: Fundamental Ratings
AMRX
VTRS
OUTLOOK RATING
1..100
8814
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
12
Undervalued
PROFIT vs RISK RATING
1..100
41100
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
4351
P/E GROWTH RATING
1..100
231
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (12) in the null industry is significantly better than the same rating for AMRX (99) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew significantly faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that AMRX’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as VTRS (51) in the null industry. This means that AMRX’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as AMRX (23) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXVTRS
RSI
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
68%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
59%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
66%
MACD
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
64%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
62%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 3 days ago
68%
Declines
ODDS (%)
Bearish Trend 11 days ago
75%
Bearish Trend 13 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
64%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BITU60.931.80
+3.04%
ProShares Ultra Bitcoin ETF
FBT189.142.11
+1.13%
First Trust NYSE Arca Biotech ETF
JLQD42.220.09
+0.20%
Janus Henderson Corporate Bond ETF
IQSU53.33N/A
N/A
NYLI Candriam U.S. Large Cap Equity ETF
NUAG21.28-0.02
-0.08%
Nuveen Enhanced Yield US Aggt Bd ETF